Aziz Mirette M, El-Gazzar Amira F, Elgibaly Omaima
Public Health and Community Medicine, Assiut University, Assiut, Egypt.
BMJ Sex Reprod Health. 2018 Jun 28. doi: 10.1136/bmjsrh-2017-101860.
The etonogestrel implant Implanon is a favourable and cost-effective contraceptive method for women in developing countries, and expansion of its use represents a priority for the family planning (FP) programme in Egypt. We studied the factors affecting first-year Implanon discontinuation from clients' and providers' perspectives.
We used a mixed quantitative-qualitative methodology. We conducted a household survey of Implanon clients and three focus group discussions with FP physicians and directors.
We found that 13.5% of Implanon users discontinued its use in the first year. Survival analysis found that clients who had previously used Implanon (HR 0.36, 95% CI 0.15 to 0.88) and whose husbands had secondary or a higher level of education (HR 0.36,95% CI 0.19 to 0.69) were less likely to discontinue Implanon use after the first year, while clients who experienced side effects of Implanon use were more likely to discontinue it (HR 3.6,95% CI 1.60 to 8.11). Other causes of discontinuation which emerged in the qualitative analysis were the unjustified advice for Implanon removal by non-gynaecologists, due to unrelated users' complaints, and deficient pre-insertion counselling.
Implanon has a low first-year discontinuation rate as compared with other contraceptive methods. FP clients should be given sufficient pre-insertion counselling about side effects of Implanon and duration of protection. Physicians should offer Implanon mainly to clients seeking long-term contraception in order to decrease its discontinuation rate and increase its cost effectiveness.
依托孕烯植入剂依伴侬是发展中国家女性一种理想且具成本效益的避孕方法,扩大其使用是埃及计划生育(FP)项目的一项优先任务。我们从服务对象和提供者的角度研究了影响依伴侬第一年停用的因素。
我们采用了定量与定性相结合的方法。我们对依伴侬使用者进行了家庭调查,并与计划生育医生和主任进行了三次焦点小组讨论。
我们发现13.5%的依伴侬使用者在第一年停用了该方法。生存分析发现,之前使用过依伴侬的服务对象(风险比0.36,95%置信区间0.15至0.88)以及其丈夫接受过中等或更高教育水平的服务对象(风险比0.36,95%置信区间0.19至0.69)在第一年之后停用依伴侬的可能性较小,而经历过依伴侬使用副作用的服务对象更有可能停用(风险比3.6,95%置信区间1.60至8.11)。定性分析中出现的其他停用原因是,非妇科医生因使用者无关的投诉而给出的不合理的取出依伴侬建议,以及插入前咨询不足。
与其他避孕方法相比,依伴侬第一年的停用率较低。计划生育服务对象应在插入依伴侬前得到关于其副作用和保护期限的充分咨询。医生应主要向寻求长期避孕的服务对象提供依伴侬,以降低其停用率并提高其成本效益。